Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-11-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司自愿披露关于欧盟委员会批准百悦泽（泽布替尼胶囊）用于治疗边缘区淋巴瘤成人患者的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from BeiGene Ltd. regarding the voluntary disclosure of the European Commission's approval of their drug BeiYueZe (Zanubrutinib capsules) for treating adult patients with relapsed/refractory marginal zone lymphoma. The text includes details about the drug, clinical trial data supporting the approval, and risk disclosures. It is a regulatory announcement about a product approval and related business impact, not a financial report, earnings release, or management discussion. The document length is about 2106 characters, which is short and typical for a regulatory announcement. There is no financial data, no voting results, no management changes, no capital updates, no legal proceedings, no merger activity, and no executive compensation details. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-11-02 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, as required under the Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It details share issuance under share award plans, share option exercises, and provides specific data on share counts, issuance prices, and dates. The document also includes confirmations that the share issuances were duly authorized and comply with regulatory requirements. The document length is about 3090 characters, which is relatively short but contains detailed share issuance data rather than just an announcement of a report. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or a simple announcement of a report publication. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-11-01 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure report related to changes in issued share capital and/or share repurchases by the company 百濟神州有限公司, registered in the Cayman Islands and listed on the Hong Kong Stock Exchange. It references specific Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A) which require disclosure of share capital changes. The document details share issuance under a share award plan, including dates, share quantities, and prices. It also includes confirmations that the share issuances were authorized and complied with regulatory requirements. The document length is about 3,022 characters, which is relatively short but contains detailed share issuance data, not just an announcement of a report. This fits the category of Share Issue/Capital Change (SHA) as it reports on new share issues and changes in capital structure. It is not a general regulatory filing or a report publication announcement because it contains substantive data on share issuance events.
2022-10-31 Chinese
港股公告：审计委员会会议日期
Regulatory Filings Classification · 95% confidence The document is a short announcement (679 characters) from BeiGene, Ltd. regarding the date of an upcoming Audit Committee meeting scheduled for November 9, 2022. It states that the meeting will review and approve financial results for the three and nine months ended September 30, 2022, prepared under US GAAP and SEC rules. The document does not contain any actual financial data or detailed financial statements; it merely announces the meeting date and the agenda. According to the 'Menu vs Meal' rule, this is an announcement about a future report or event, not the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2022-10-30 Chinese
百济神州有限公司自愿披露关于百悦泽（泽布替尼胶囊）获欧洲药品管理局人用药品委员会积极意见的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from BeiGene Ltd. regarding the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) positive opinion on the drug BeiYueZe (Zebutinib capsules) for marketing authorization. It details the drug's clinical trial background, regulatory process, and potential impact on the company. The document is an official announcement of a regulatory development related to the company's product, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is short (1837 characters) and it is a disclosure of regulatory progress and risk factors. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-10-14 Chinese
百济神州有限公司自愿披露关于百悦泽（泽布替尼胶囊）临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding clinical trial progress of their drug BeiYueZe (Zebutinib capsules). It details results from a global Phase 3 ALPINE clinical trial, including efficacy and safety outcomes, and discusses potential regulatory approval uncertainties and investment risks. The document is an announcement of clinical trial progress and risk factors, not a financial report, earnings release, or regulatory filing about financials. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it provides substantive information rather than just announcing a report release. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial progress and risk disclosures, which do not fit other specific categories.
2022-10-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.